Dissecting cell type-specific metabolism in pancreatic ductal adenocarcinoma
- Massachusetts Institute of Technology, United States
- University of Massachusetts, Amherst, United States
- Harvard Medical School, United States
- Cold Spring Harbor Laboratory, United States
- University of Cambridge, United Kingdom
Abstract
Tumors are composed of many different cell types including cancer cells, fibroblasts, and immune cells. Dissecting functional metabolic differences between cell types within a mixed population can be challenging due to the rapid turnover of metabolites relative to the time needed to isolate cells. To overcome this challenge, we traced isotope-labeled nutrients into macromolecules that turn over more slowly than metabolites. This approach was used to assess differences between cancer cell and fibroblast metabolism in murine pancreatic cancer organoid-fibroblast co-cultures and tumors. Pancreatic cancer cells exhibited increased pyruvate carboxylation relative to fibroblasts, and this flux depended on both pyruvate carboxylase and malic enzyme 1 activity. Consequently, expression of both enzymes in cancer cells was necessary for organoid and tumor growth, demonstrating that dissecting the metabolism of specific cell populations within heterogeneous systems can identify dependencies that may not be evident from studying isolated cells in culture or bulk tissue.
Data availability
All data generated or analyzed during this study are included in the manuscript and supporting files.
Article and author information
Author details
Nicholas J Matheson
Matthew G Vander Heiden
Funding
Damon Runyon Cancer Research Foundation (DRG-2241-15)
- Allison N Lau
National Cancer Institute (U54CA163109)
- Vasilena Gocheva
Human Frontiers Science Program (LT000195/2015-L)
- Giulia Biffi
EMBO (ALTF 1203-2014)
- Giulia Biffi
Howard Hughes Medical Institute
- Tyler Jacks
- Matthew G Vander Heiden
MRC (CSF MR/P008801/1)
- Nicholas J Matheson
NHSBT (WPA15-02)
- Nicholas J Matheson
NIHR Cambridge BRC
- Nicholas J Matheson
National Institutes of Health (R01CA211184)
- Omer Yilmaz
National Institutes of Health (R01CA034992)
- Omer Yilmaz
Lustgarten Foundation
- Matthew G Vander Heiden
Damon Runyon Cancer Research Foundation (DRG-2367-19)
- Sharanya Sivanand
Stand Up To Cancer
- Matthew G Vander Heiden
MIT Center for Precision Cancer Medicine
- Matthew G Vander Heiden
Ludwig Center at MIT
- Tyler Jacks
- Matthew G Vander Heiden
Emerald Foundation
- Matthew G Vander Heiden
National Cancer Institute (R01CA168653)
- Matthew G Vander Heiden
National Cancer Institute (R01CA201276)
- Matthew G Vander Heiden
National Cancer Institute (R35CA242379)
- Matthew G Vander Heiden
National Cancer Institute (P30CA14051)
- Matthew G Vander Heiden
Damon Runyon Cancer Research Foundation (DRG-2299-17)
- Evan C Lien
National Cancer Institute (K99CA234221)
- Allison N Lau
National Institutes of Health (T32GM007287)
- Zhaoqi Li
- Kiera M Sapp
Jane Coffin Childs Memorial Fund for Medical Research
- Alicia M Darnell
- Vasilena Gocheva
Swedish Foundation for Strategic Research
- Raphael Ferreira
Knut and Alice Wallenberg Foundation
- Raphael Ferreira
Barbro Osher Pro Suecia Foundation
- Raphael Ferreira
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Ethics
Animal experimentation: All animal studies were approved by the MIT Committee on Animal Care under protocol #0119-001-22.
Copyright
© 2020, Lau et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 7,176
- views
-
- 1,243
- downloads
-
- 69
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Dissecting cell type-specific metabolism in pancreatic ductal adenocarcinoma
eLife 9:e56782.
https://doi.org/10.7554/eLife.56782
Further reading
-
- Cancer Biology
- Computational and Systems Biology
Effects from aging in single cells are heterogenous, whereas at the organ- and tissue-levels aging phenotypes tend to appear as stereotypical changes. The mammary epithelium is a bilayer of two major phenotypically and functionally distinct cell lineages: luminal epithelial and myoepithelial cells. Mammary luminal epithelia exhibit substantial stereotypical changes with age that merit attention because these cells are the putative cells-of-origin for breast cancers. We hypothesize that effects from aging that impinge upon maintenance of lineage fidelity increase susceptibility to cancer initiation. We generated and analyzed transcriptomes from primary luminal epithelial and myoepithelial cells from younger <30 (y)ears old and older >55 y women. In addition to age-dependent directional changes in gene expression, we observed increased transcriptional variance with age that contributed to genome-wide loss of lineage fidelity. Age-dependent variant responses were common to both lineages, whereas directional changes were almost exclusively detected in luminal epithelia and involved altered regulation of chromatin and genome organizers such as SATB1. Epithelial expression variance of gap junction protein GJB6 increased with age, and modulation of GJB6 expression in heterochronous co-cultures revealed that it provided a communication conduit from myoepithelial cells that drove directional change in luminal cells. Age-dependent luminal transcriptomes comprised a prominent signal that could be detected in bulk tissue during aging and transition into cancers. A machine learning classifier based on luminal-specific aging distinguished normal from cancer tissue and was highly predictive of breast cancer subtype. We speculate that luminal epithelia are the ultimate site of integration of the variant responses to aging in their surrounding tissue, and that their emergent phenotype both endows cells with the ability to become cancer-cells-of-origin and represents a biosensor that presages cancer susceptibility.
-
- Cancer Biology
Chemotherapy is widely used to treat lung adenocarcinoma (LUAD) patients comprehensively. Considering the limitations of chemotherapy due to drug resistance and other issues, it is crucial to explore the impact of chemotherapy and immunotherapy on these aspects. In this study, tumor samples from nine LUAD patients, of which four only received surgery and five received neoadjuvant chemotherapy, were subjected to scRNA-seq analysis. In vitro and in vivo assays, including flow cytometry, immunofluorescence, Seahorse assay, and tumor xenograft models, were carried out to validate our findings. A total of 83,622 cells were enrolled for subsequent analyses. The composition of cell types exhibited high heterogeneity across different groups. Functional enrichment analysis revealed that chemotherapy drove significant metabolic reprogramming in tumor cells and macrophages. We identified two subtypes of macrophages: Anti-mac cells (CD45+CD11b+CD86+) and Pro-mac cells (CD45+CD11b+ARG +) and sorted them by flow cytometry. The proportion of Pro-mac cells in LUAD tissues increased significantly after neoadjuvant chemotherapy. Pro-mac cells promote tumor growth and angiogenesis and also suppress tumor immunity. Moreover, by analyzing the remodeling of T and B cells induced by neoadjuvant therapy, we noted that chemotherapy ignited a relatively more robust immune cytotoxic response toward tumor cells. Our study demonstrates that chemotherapy induces metabolic reprogramming within the tumor microenvironment of LUAD, particularly affecting the function and composition of immune cells such as macrophages and T cells. We believe our findings will offer insight into the mechanisms of drug resistance and provide novel therapeutic targets for LUAD in the future.
